Welcome to our dedicated page for Kodiak Sciences news (Ticker: KOD), a resource for investors and traders seeking the latest updates and insights on Kodiak Sciences stock.
Kodiak Sciences Inc. develops retinal medicines as a precommercial biotechnology company focused on diseases that can cause vision loss. News about KOD centers on the ABC Platform and ABCD Platform, the anti-VEGF biologic Zenkuda (tarcocimab tedromer), and bispecific programs including KSI-501 and KSI-101.
Recurring updates cover clinical data in diabetic retinopathy, wet age-related macular degeneration and macular edema secondary to inflammation, along with scientific conference presentations, financial results and capital formation. Company announcements also discuss pipeline expansion into multi-target retinal and ocular disease approaches, including programs directed at inflammation, geographic atrophy and glaucoma optic neuropathy.
Kodiak Sciences Inc. (Nasdaq: KOD) announced that new data from the ongoing Phase 1b study of KSI-301, a novel anti-VEGF antibody biopolymer conjugate, will be presented at the ASRS 2020 Virtual Annual Meeting. The presentation will take place on July 10, 2020, showcasing results from 121 patients with wet AMD, diabetic macular edema, and retinal vein occlusion. CEO Victor Perlroth highlighted the promising safety and efficacy data accumulated across over 150 patient-years. A related R&D webinar is set for July 27, 2020, to discuss the implications of these findings.